| Japanese |
|---|
| Title | 中枢性ベンゾジアゼピン受容体イメージング剤123I - イオマゼニルの第3相臨床試験 (第2報) - 中枢神経変性疾患および精神神経障害における臨床的有用性の検討 - |
|---|
| Subtitle | 技術報告 |
|---|
| Authors | 鳥塚莞爾*1, 上村和夫*2, 融道男*3, 篠原幸人*4, 西村恒彦*5, 米倉義晴*6, 中川原譲二*7, 松田博史*8, 坂井文彦*9, 松田一己*10, 福山秀直*11, 森本清*12 |
|---|
| Authors(kana) | |
|---|
| Organization | *1福井医科大学(現 ; 京都大学名誉教授), *2秋田県立脳血管研究センター, *3東京医科歯科大学神経精神科, *4東海大学第五内科(神経内科), *5大阪大学トレーサ情報解析学講座, *6京都大学脳病態生理学講座(現 ; 福井医科大学高エネルギー医学研究センター), *7中村記念病院脳神経外科, *8国立精神神経センター武蔵病院放射線診療部, *9北里大学内科, *10国立療養所静岡東病院(てんかんセンター)脳神経外科, *11京都大学神経内科(現 ; 脳病態生理学講座), *12香川医科大学精神神経科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 33 |
|---|
| Number | 3 |
|---|
| Page | 303-318 |
|---|
| Year/Month | 1996/3 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」中枢性ベンゾジアゼピン受容体(BZR)に特異的に結合する123I-イオマゼニルの臨床的有用性について, 中枢神経変性疾患169例および神経症性障害を中心とした精神神経障害37例において検討した. 痴呆において本剤の3時間後像(後期像)での集積低下の程度は知的機能指標と相関した. パーキンソン病および脊髄小脳変性症においては, 発症後の経過年数や重症度の進行に伴い, 脳血流像よりも後期像での集積低下が著しい領域の割合が増加した. 精神神経障害では, 神経症性障害等での不安スケールが増すに従い, 全脳における本剤後期像/早期像カウント比が低下し, また, パニック障害では発作の重症度の上昇とともに, 後期像での小脳に対する前頭葉, 側頭葉および頭頂葉のカウント比が低下した. 本剤は変性疾患での神経細胞障害や不安の病態に関与する神経受容体の異常など, 詳細な脳病態生理の把握が可能で, 各種脳疾患の病態診断に有効であることが示された. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 123I-Iomazenil, Benzodiazepine receptor, Degenerative neurological disease, Mental disorders, Neuronal damage. |
|---|
| English |
|---|
| Title | A Phase 3 Clinical Trial of 123I - Iomazenil, a New Central - Type Benzodiazepine Receptor Imaging Agent (Part 2) - Report on Clinical Usefulness in Diagnosis of Degenerative Neurological Diseases and Mental Disorders - |
|---|
| Subtitle | Technical Reports |
|---|
| Authors | Kanji TORIZUKA*1, Kazuo UEMURA*2, Michio TORU*3, Yukito SHINOHARA*4, Tsunehiko NISHIMURA*5, Yoshiharu YONEKURA*6, Jyoji NAKAGAWARA*7, Hiroshi MATSUDA*8, Fumihiko SAKAI*9, Kazumi MATSUDA*10, Hidenao FUKUYAMA*11, Kiyoshi MORIMOTO*12 |
|---|
| Authors(kana) | |
|---|
| Organization | *1Fukui Medical School(Currently Professor Emeritus, Kyoto University), *2Akita Research Institute for Brain and Blood Vessels, *3Department of Psychiatry, Tokyo Medical and Dental University, *4Department of Neurology, Tokai University, *5Department of Tracer Kinetics, Osaka University, *6Department of Brain Pathophysiology, Kyoto University(currently Biomedical Imaging Research Center, Fukui Medical School), *7Department of Neurosurgery, Nakamura Memorial Hospital, *8Department of Radiology, National Center Hospital for Mental, Nervous, and Muscular Disorders, NCNP, *9Department of Internal Medicine, Kitasato University, *10Department of Neurosurgery, National Epilepsy Center, Shizuoka-Higashi Hospital, *11Department of Neurology(currently Department of Brain Pathophysiology), Kyoto University, *12Department of Neuropsychiatry, Kagawa Medical School |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 33 |
|---|
| Number | 3 |
|---|
| Page | 303-318 |
|---|
| Year/Month | 1996/3 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]Iomazenil(IMZ)is a partial inverse agonist of central-type benzodiazepine receptors(BZR)which binds specifically to BZR with high affinity. A multicenter Phase 3 clinical study was performed to evaluate the clinical usefulness of 123I-IMZ-SPECT in the diagnosis of brain disorders in 169 patients with degenerative neurological diseases and 37 patients with mental disorders such as neurotic, stress-related and somatoform disorders. In dementia, the decrease in activity in late images, obtained three hours after administration of 123I-IMZ, correlated negatively with the dementia score. In Parkinson's disease and spinocerebellar degeneration. 123I-IMZ showed a more profound decrease in uptake in late images than seen in the cerebral blood flow(CBF)images, and this decrease was in proportion to the duration and severity of the illness. In mental disorders, the ratio of the late to early image counts showed a negative correlation with Hamilton's anxiety scale in all regions in the brain cortices. In panic disorders, the ratio of the cerebral count to the cerebellar count in the late images correlated negatively with the severity of the attack in the frontal, temporal and parietal cortices. These results suggest that 123I-IMZ-SPECT enables us to evaluate the neuronal damage in degenerative diseases and the decrease in the BZR binding potential in mental disorders. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 123I-Iomazenil, Benzodiazepine receptor, Degenerative neurological disease, Mental disorders, Neuronal damage. |
|---|